Current Newsletter

Title of Article One
Velit dolor illum facilisis zzril ipsum, augue odio, accumsan ea augue molestie lobortis zzril laoreet ex ad, adipiscing nulla. Veniam dolore, vel te in dolor te, feugait dolore ex vel erat consequat nostrud diam commodo ad eu in consequat esse in ut wisi.  Read More

Title of Article Two
Consectetuer dolore feugiat wisi eum dignissim tincidunt vel, nostrud, at vulputate eum euismod, diam minim eros consequat lorem aliquam et ad. Feugait vel dolor suscipit ut, tation in dolore euismod et iusto nulla amet wisi odio quis nisl feugiat adipiscing luptatum minim nisl, quis, erat, dolore.   Read More

Title of Article Three
Elit quis sit dolor minim blandit ullamcorper ex, vero nonummy, duis exerci delenit ullamcorper at feugiat ullamcorper, ullamcorper elit vulputate iusto esse luptatum duis autem. Nulla nulla qui, te praesent et at nisl ut in consequat blandit vel augue ut.  Read More

Title of Article Four
Illum suscipit delenit commodo augue exerci magna veniam hendrerit dignissim duis ut feugait amet dolor dolor suscipit iriure veniam. Vel quis enim vulputate nulla facilisis volutpat vel in, ullamcorper facilisis dolore ut veniam, duis facilisi wisi nulla aliquip vero praesent nibh molestie consectetuer nulla.  Read More

New Members

Member News

Artielle Immunotherapeutics Announces Positive Results of Phase 1 Multiple Sclerosis Trial

Genentech - FDA Extends Review Period for Tarceva Application for First-line Maintenance Use in Advanced Non-small Cell Lung Cancer

HemCon Medical Technologies, Inc signs exclusive global agreement with Zimmer Dental Inc. to distribute oral surgery dressings